This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lo-Man, R. Articles by Leclerc, C. Search for Related Content PubMed PubMed Citation Articles by Lo-Man, R. Articles by Leclerc, C.

A Fully Synthetic Immunogen Carrying a Carcinoma-associated Carbohydrate for Active Specific Immunotherapy¹

Unité de Biologie des Régulations Immunitaires [R. L-M., E. D., C. L.] and Unité de Chimie Organique [S. B., S. V-G., D. C.], Institut Pasteur, 75724 Paris, Cedex 15, France

Aberrant glycosylation of mucins leads to the exposure of cryptic carbohydrate antigens at the surface of carcinoma cells, which, therefore, represent potent targets for anticancer therapeutic vaccines. To date, the development of immunogens to stimulate immune response to such saccharidic antigens is based on carbohydrate conjugation to carrier proteins. However, these traditional protein conjugates are poorly defined in chemical composition and structure. As an alternative, we synthesized a multiple antigenic O-linked glycopeptide (MAG) carrying the carbohydrate Tn antigen associated with a CD4⁺ T-cell epitope (MAG:Tn-PV). This fully synthetic immunogen is highly defined in composition and carries a high saccharidic epitope ratio over the entire molecule. The MAG:Tn-PV was able to induce anti-Tn IgG antibodies that recognize human tumor cell lines. A therapeutic immunization protocol performed with this fully synthetic immunogen increased the survival of tumor-bearing mice. Thus, the accurately defined and versatile MAG system represents an efficient strategy to induce carbohydrate-specific antitumor immune responses but may also be applicable to the prevention of infectious diseases, if it is based on bacterial oligosaccharides.

This article has been cited by other articles:

				T. Buskas, S. Ingale, and G.-J. Boons Glycopeptides as versatile tools for glycobiology Glycobiology, August 1, 2006; 16(8): 113R - 136R. [Abstract] [Full Text] [PDF]

				R. Lo-Man, S. Vichier-Guerre, R. Perraut, E. Deriaud, V. Huteau, L. BenMohamed, O. M. Diop, P. O. Livingston, S. Bay, and C. Leclerc A Fully Synthetic Therapeutic Vaccine Candidate Targeting Carcinoma-Associated Tn Carbohydrate Antigen Induces Tumor-Specific Antibodies in Nonhuman Primates Cancer Res., July 15, 2004; 64(14): 4987 - 4994. [Abstract] [Full Text] [PDF]

				R. Lo-Man, S. Vichier-Guerre, S. Bay, E. Deriaud, D. Cantacuzene, and C. Leclerc Anti-Tumor Immunity Provided by a Synthetic Multiple Antigenic Glycopeptide Displaying a Tri-Tn Glycotope J. Immunol., February 15, 2001; 166(4): 2849 - 2854. [Abstract] [Full Text] [PDF]

				M. Inoue, S. Takahashi, I. Yamashina, M. Kaibori, T. Okumura, Y. Kamiyama, S. Vichier-Guerre, D. Cantacuzène, and H. Nakada High Density O-Glycosylation of the MUC2 Tandem Repeat Unit by N-Acetylgalactosaminyltransferase-3 in Colonic Adenocarcinoma Extracts Cancer Res., February 1, 2001; 61(3): 950 - 956. [Abstract] [Full Text]